Download full-text PDF

Source

Publication Analysis

Top Keywords

[neoplasms greater
4
greater omentum
4
omentum children]
4
[neoplasms
1
omentum
1
children]
1

Similar Publications

Background: Virtual follow-up (VFU) has the potential to enhance cancer survivorship care. However, a greater understanding is needed of how VFU can be optimized.

Objective: This study aims to examine how, for whom, and in what contexts VFU works for cancer survivorship care.

View Article and Find Full Text PDF

Disparities in time to treatment initiation of invasive lung cancer among Black and White patients in Tennessee.

PLoS One

January 2025

Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD, United States of America.

Article Synopsis
  • The study investigates disparities in treatment initiation times for lung cancer between Black and White patients in Tennessee, revealing that Black patients generally face delays.
  • The analysis of 42,970 lung cancer cases identified that younger Black patients and married White patients had the highest risks for late treatment initiation.
  • The findings suggest a need for further research to better understand the factors contributing to these disparities in treatment timing between racial groups.
View Article and Find Full Text PDF
Article Synopsis
  • This study focused on detecting Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 in breast cancer to help categorize the disease and guide treatment choices.
  • Researchers compared two preservation methods for breast tissue samples: traditional formalin fixation and RNAlater, utilizing Immunohistochemistry (IHC) and Quantitative Polymerase Chain Reaction (qPCR) for analysis.
  • Findings revealed that ER and PR were positive in 60% of samples, while HER-2 was positive in only 25%, with no significant statistical difference between the results from the two preservation methods.
View Article and Find Full Text PDF

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.

JAMA Netw Open

January 2025

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.

Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).

Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.

View Article and Find Full Text PDF

Sex differences in the outcomes of advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICIs) and the profiles of tumor-infiltrating immune cells (TIICs) remain unclear. We retrospectively evaluated data from 563 patients with RCC receiving systemic therapy, including first-line dual ICI combinations (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!